Prognosis
AstraZeneca Rises as Key Lung Cancer Drug Scores Another Win
- Trial data shows blockbuster drug slows disease progression
- Tagrisso is already AstraZeneca’s top-selling cancer drug
This article is for subscribers only.
AstraZeneca Plc shares rose after trial data showed Tagrisso slowed disease progression in patients with advanced lung cancer in another win for the pharmaceutical giant’s blockbuster drug.
The trial looked at Tagrisso as a maintenance therapy for patients with non-small cell lung cancer and a specific genetic mutation, where there is no targeted treatment available.